Sionna Therapeutics is trading at $5.16, down 6.35%, amid a broader risk-off session and pressure on growth-oriented assets from rising Treasury yields near a 19-year high.
- Nasdaq is down 0.79%, while biotechnology ETF XBI is down 2.04%.
- No new company-specific announcement was identified on September 24, 2026.
- Investors may still be weighing the September 14 disclosure that SION-719 failed its key trial endpoint and the company cut its workforce by 46%; that news is not fresh.